Analytical considerations for cfDNA biomarker analysis powered by NGS

The analysis of cell-free DNA (cfDNA) biomarkers using next-generation sequencing (NGS) is becoming increasingly important in cancer research due to its potential applications in early cancer detection, therapy selection, and minimal residual disease (MRD) monitoring. However, there are several challenges that need to be addressed in order to ensure accurate and reliable analysis of cfDNA. In this context, the use of NGS-based assays can provide high sensitivity and specificity in detecting low-level mutations in cfDNA. The success of NGS-based cfDNA analysis depends on several analytical considerations including overcoming sequencing reaction errors, enrichment biases and false positives to detect variant alleles down to 0.1% frequency.

In this webinar, you will learn about

The value of cfDNA in cancer research
The challenges associated with cfDNA analysis, and
Analytical considerations for NGS-based cfDNA biomarker analysis

About the speaker

Krishna Amin, Senior Global Product Manager-Targeted Genomics

QIAGEN

Krishna Amin hold Bachelor of Science in Biochemistry from University of Maryland, QIAGEN. Since joining QIAGEN in 2011, she has worked with various technology development groups working on qPCR and next-generation sequencing (NGS) technologies. Currently, she leads the Targeted DNAseq portfolio at QIAGEN.

Leif Schauser, Director, Product Management, Genome Analysis

QIAGEN

Leif Schauser holds a Ph.D. in plant molecular genetics from Aarhus University, Denmark. He did his postdoctoral training in Norwich, UK, before working as a professor in bioinformatics at Aarhus University. In 2013 Leif joined CLC bio, just before its acquisition by QIAGEN.